Navigation Links
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
Date:6/4/2008

e for us this year. We are extremely pleased to have assembled such a strong group of institutional investors, which is a testament to our accomplished management team and to the trust in our robust oncology pipeline."

The securities sold in the private offering have not been registered under the Securities Act of 1933 and may not be resold absent registration under or exemption from such Act. Arno has agreed to file with the Securities and Exchange Commission a registration statement for the resale of the securities held by the investors in the offering by August 2, 2008. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Arno Therapeutics

Arno Therapeutics is a biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno is initially focusing its efforts on developing its lead compound, AR-67, a novel anti-cancer agent. AR-67 is a third generation campthothecin analogue currently in Phase I clinical trials that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing AR-12 and AR-42, two novel, preclinical oncology products. A key component of the Company's strategy is to acquire global rights to additional product candidates for the treatment of cancer while continuing to use its technology to develop and commercialize new products and line extensions. For more information on Arno please visit http://www.arnothera.com.

This press release contains statements that are not historical in nature but are forward-looking. These statements are often, but not alwa
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
10. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
11. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... R.I. , Sept. 19, 2014 Larry ... CVS ), will speak before the National Press ... will discuss the company,s recent move to stop selling tobacco ... shape the future of health. "Dramatic changes in ... health care providers and government," Merlo has said. "CVS Health ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... Surgeons at Self Regional Healthcare,s South Carolina Spine Center ... variety of spinal conditions in its new advanced surgical ... Already recognized by leading health care ratings organization ... continues its commitment to advanced spinal care by becoming ...
... announced today the company has reached another major milestone ... management team roster. DiFUSION Technologies is ... commercialization of its proprietary CleanFUZE ™ anti-microbial technology ... line of Posterior Interbody products. "In ...
Cached Medicine Technology:Self Regional Healthcare Becomes First in the Southeast to Treat Spine Patients Using Advanced Integrated Operating Room Technology From Brainlab 2DiFUSION Technologies Adds Accomplished Senior Management Team 2DiFUSION Technologies Adds Accomplished Senior Management Team 3DiFUSION Technologies Adds Accomplished Senior Management Team 4DiFUSION Technologies Adds Accomplished Senior Management Team 5
(Date:9/19/2014)... Hastings and Hastings, a discount accident lawyer in Phoenix, ... record number of visitors to its new Phoenix personal injury ... cases as well as auto accident cases and slip & ... and others. Having served the state of Arizona for over ... time when it comes to dedicated and focused personal injury ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... (HealthDay News) -- Although there is mounting evidence ... middle-aged and older adults in the United States ... to new research. Less than one-quarter of ... by the Department of Health and Human Services, ... for promoting health and fitness and staying independent, ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... statin medication caused some patients to develop Type 2 ... litigation now underway in U.S. District Court, District of ... Status Report issued on September 12, 2014, discovery is ... things, the report noted that Pfizer, Inc., the manufacturer ...
(Date:9/19/2014)... In partnership with Raw Beauty NYC, OC healthcare agency ... social media efforts. StudioPMG is honored to be a part ... beauty as it applies to disabled women. , The ... and Vanessa Silberman, who wanted to create a photo exhibit ... Wendy Crawford, Susan Solman and Sabrina Cohen later joined in ...
Breaking Medicine News(10 mins):Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2
... in soy foods such as tufu, soy milk or soy ... , ,However, the soy foods should be made from raw ... this, soy-supplemented muffins, cereals or nutritional bars do not offer ... prepare these foods. ,Beneficial soy products include soy ...
... that resveratrol, a compound found in grapes and ... peptides, which cause the telltale senile plaques of ... antioxidant compounds with potential neuroprotective activities. Resveratrol is ... widely studied for their health benefits. It is ...
... New bird flu vaccine is to be developed from this ... from wild birds which has killed wild and migratory poultry ... Organization (WHO). //WHO has given orders to the Wildlife Conservation ... very helpful during a possible attack. The WCS team of ...
... fact that one third of our lifetime is spent in sleep. ... quantity. A new study conducted reveals the lack of adequate sleep ... And the mail villain held responsible- Of course stress! ... 1003 adults by the Gallup Organization for International Longevity Center-USA to ...
... aging molecule, Klotho named after the Greek God who spins ... believed to play a very important role in the aging ... symptoms of aging, while over expression is associated with an ... the blood. The working mechanism however remained unclear. A ...
... sounded against bird flu at the Kaziranga National Park in ... sanctuary around this time every year. // ,Wildlife staff ... park have been alerted about the possibility of migratory birds ... immediately if any unusual avian behaviour. A veterinary doctor has ...
Cached Medicine News:Health News:Lack of adequate sleep among people over 50 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: